Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2022-01-31 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
First Regulatory Approval in Europe for DMX-200 FSGS Study 3 pages 305.1KB
Regulatory Filings
2022-01-31 English
Quarterly Appendix 4C and Activities Report 10 pages 535.4KB
Regulatory Filings
2022-01-27 English
Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India 5 pages 390.0KB
Regulatory Filings
2022-01-10 English
Ethics Approval in Australia for Phase 3 COVID-19 Study 4 pages 354.3KB
Regulatory Filings
2021-12-22 English
Dimerix Receives Further MRFF Funding for DMX-200 4 pages 332.7KB
Regulatory Filings
2021-12-21 English
Pause in Trading 1 page 108.4KB
Regulatory Filings
2021-12-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.